CA
ARCT icon

Calton & Associates’s Arcturus Therapeutics ARCT Stock Holding History

Calton & Associates’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-11,190
Closed -$206K – 449
2025
Q3 		$206K Buy
11,190
+300
+3% +$4.82K 0.03% 399
2025
Q2 		$142K Buy
+10,890
New +$129K 0.02% 372
2018
Q1 		– Sell
-28
Closed – – 388
2017
Q4 		$0 Buy
+28
New +$252 ﹤0.01% 1478

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Calton & Associates's ARCT Position: Q4 2025 in Review

Calton & Associates sold out of Arcturus Therapeutics (ARCT) in Q4 2025, closing a stake of 11,190 shares — an estimated $206K sold.

Calton & Associates first reported a position in ARCT in Q4 2017 and held it in 3 quarters. The position peaked at $206K in Q3 2025. 120 funds tracked by Wall St. Rank hold ARCT as of Q4 2025.

  • Calton & Associates reported no remaining Arcturus Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Calton & Associates sold 11,190 Arcturus Therapeutics shares in Q4 2025, an estimated $206K.
  • Calton & Associates first reported a position in Arcturus Therapeutics in Q4 2017 and held it in 3 quarters.
  • Calton & Associates's Arcturus Therapeutics position peaked at $206K in Q3 2025.
  • 120 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q4 2025.

Based on Calton & Associates's 13F filing for Q4 2025, filed 10 Feb 2026.